Premium
Retinoblastoma‐derived peptides directly inhibit the CMG helicase and impair proliferation of cancer cells
Author(s) -
Larratta Auston J.,
Borysov Sergiy
Publication year - 2018
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.2018.32.1_supplement.531.22
Subject(s) - helicase , rna helicase a , cancer cell , retinoblastoma , cancer , cancer research , in vitro , biology , microbiology and biotechnology , chemistry , biochemistry , genetics , gene , rna
The CMG helicase is the main replicative helicase. Circumstantial evidence suggests that interference with the function of this helicase is detrimental for cancer cells, while tolerable for normal healthy cells, pointing to the CMG helicase as an ideal novel target for cancer treatment. Previous studies identified Retinoblastoma (Rb) protein as a potent native inhibitor of the helicase activity. For the purpose of drug discovery, here we explore Rb‐derived peptides for their abilities to inhibit the CMG helicase and proliferation of cancer cells. For the first time, we showed that Rb‐derived peptides directly inhibited activity of human CMG helicase, as assessed in an in vitro helicase assay . Importantly, Rb‐derived peptides caused a substantial decrease in the proliferation of cancer cells in vitro . Our results further support the idea of targeting CMG helicase for cancer treatment and developing novel anti‐cancer therapeutic agents based on Rb‐derived peptides. This abstract is from the Experimental Biology 2018 Meeting. There is no full text article associated with this abstract published in The FASEB Journal .